Beta Bionics, Inc. (BBNX) is a Healthcare stock trading at $13.88 (as of 2026-06-18), with a market capitalization of $554.79M and a trailing P/E of -10.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Beta Bionics, Inc. designs, develops, and commercializes medical device solutions for insulin-requiring people with diabetes. Its main product is the iLet bionic pancreas for type 1 diabetes, and it also develops additional automated insulin delivery and related systems, including collaborations for glucagon formulation and an automated delivery system.